Hyperoxaluria is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hyperoxaluria have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hyperoxaluria compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Hyperoxaluria

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hyperoxaluria overview

Hyperoxaluria, a rare condition, manifests with recurrent kidney and bladder stones, often progressing to life-threatening end-stage renal disease (ESRD). The condition arises from the overproduction of oxalate, leading to abnormally high levels in urine. Primary hyperoxaluria types 1, 2, and 3 are caused by mutations in the AGXT, GRHPR, and HOGA1 genes, respectively. These genes guide the production of enzymes crucial for breaking down amino acids and other compounds. The enzyme from the HOGA1 gene plays a role in amino acid breakdown, resulting in the formation of glyoxylate, further processed by enzymes from the AGXT and GRHPR genes.

For a complete picture of PTSR and LoA scores for drugs in Hyperoxaluria, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.